Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study

BMJ Open

Volumn 5, Issue 12, 2015, Pages

  Patel, Rashmi ^a   Reiss, Peter ^a   Shetty, Hitesh ^b   Broadbent, Matthew ^b   Stewart, Robert ^a   McGuire, Philip ^a   Taylor, Matthew ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; NATIONAL HEALTH SERVICE; RETROSPECTIVE STUDY; UNITED KINGDOM; CHEMICALLY INDUCED; COMPLICATION; DEPRESSION; DRUG ADMINISTRATION; ELECTRONIC HEALTH RECORD; PSYCHOLOGY; REGISTER; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSION; DRUG ADMINISTRATION SCHEDULE; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INCIDENCE; MALE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; UNITED KINGDOM; VENLAFAXINE HYDROCHLORIDE;

EID: 84960408767     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-008341     Document Type: Article

References (37)

1. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010;121:404-14.
2. Chun BJDH, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. Bipolar Disord 2004;6:32-42.
3. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
4. Etain B, Lajnef M, Bellivier F, et al. Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States. J Clin Psychiatry 2012;73:e561-6.
5. Judd LL, Schettler PJ, Akiskal HS, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003;6:127-37.
6. Suppes T, Leverich GS, Keck Jr PE, et al. The Stanley Foundation Bipolar Treatment Outcome Network: II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001;67:45-59.
7. Berk M, Dodd S. Are treatment emergent suicidality and decreased response to antidepressants in younger patients due to bipolar disorder being misdiagnosed as unipolar depression? Med Hypotheses 2005;65:39-43.
8. Bowden CL. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 2005;84:117-25.
9. Stewart R, Soremekun M, Perera G, et al. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 2009;9:51.
10. Fernandes AC, Cloete D, Broadbent MT, et al. Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records. BMC Med Inform Decis Mak 2013;13:71.
11. Patel R, Jayatilleke N, Jackson R, et al. Investigation of negative symptoms in schizophrenia with a machine learning text-mining approach. Lancet 2014;383:S16.
12. Chang CK, Hayes R, Broadbent M, et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 2010;10:77.
13. Hayes RD, Chang CK, Fernandes AC, et al. Functional status and all-cause mortality in serious mental illness. PLoS ONE 2012;7: e44613.
14. Hayes RD, Chang CK, Fernandes A, et al. Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. Drug Alcohol Depend 2011;118:56-61.
15. Wu CY, Chang CK, Robson D, et al. Evaluation of smoking status identification using electronic health records and open-text information in a large mental health case register. PLoS ONE 2013;8:e74262.
16. Wu CY, Chang CK, Hayes RD, et al. Clinical risk assessment rating and all-cause mortality in secondary mental healthcare: the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register. Psychol Med 2012;42:1581-90.
17. Gorrell G, Jackson R, Roberts A, et al. Finding Negative Symptoms of Schizophrenia in Patient Records. Proceedings of NLP Med Biol Work (NLPMedBio), Recent Adv Nat Lang Process (RANLP), Hissar, Bulgaria, 2013:9-17. http://aclweb.org/anthology/W/W13/W13-5102.pdf
18. Patel R, Shetty H, Jackson R, et al. Delays before diagnosis and initiation of treatment in patients presenting to Mental Health Services with bipolar disorder. PLoS ONE 2015;10:e0126530.
19. Joint-Formulary-Committee. British National Formulary. Pharmaceutical Press, 2013.
20. National Institute for Health and Care Excellence. CG90 Depression: the treatment and management of depression in adults. 2009.
21. StataCorp. Stata Statistical Software: Release 12. Coll Station TX StataCorp LP, 2011.
22. Benvenuti A, Rucci P, Miniati M, et al. Treatment-emergent mania/hypomania in unipolar patients. Bipolar Disord 2008;10:726-32.
23. Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004;158:773-80.
24. Wada K, Sasaki T, Jitsuiki H, et al. Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 2006;26:512-15.
25. Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014;171:1067-73.
26. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychopharmacol 1995;10(Suppl 2):15-20.
27. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol 1996;16:54S-9S.
28. Stoner SC, Williams RJ, Worrel J, et al. Possible venlafaxine-induced mania. J Clin Psychopharmacol 1999;19:184-5.
29. Shulman RB, Scheftner WA, Nayudu S. Venlafaxine-associated mania. J Clin Psychopharmacol 2001;21:239-41.
30. Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994;164:549-50.
31. Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord 1997;46:73-7.
32. Ramasubbu R. Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand 2001;104:236-9.
33. Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001;62:565-9.
34. Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry 2014;161:163-5.
35. Culpepper L. Misdiagnosis of bipolar depression in primary care practices. J Clin Psychiatry 2014;75:e05.
36. Moore RA, Kalso EA, Wiffen PJ, et al. Antidepressant drugs for neuropathic pain-an overview of Cochrane reviews. Cochrane Library, 2015.
37. Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition - recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88.